Breaking News

BiondVax Inks Agreement to Develop Pipeline of NanoAb Therapies

To collaborate on the development of innovative nanosized antibodies targeting infectious diseases and other illnesses.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for infectious diseases and other illnesses, signed an agreement with the Max Planck Society, and the University Medical Center Göttingen (UMG), both in Germany, to collaborate on the development of innovative nanosized antibodies (NanoAbs). BiondVax will have an exclusive option for an exclusive worldwide license for further development and commercialization of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters